It is also reported that inhibiting NRP1 using monoclonal antibodies could inhibit the formation of integrin α5β1-NRP1 complex, the activation of FAK pathway and the adhesion of tumor cells to fibronectin [39, 40]. The gene discussed is FN1; the disease is neoplasm.